{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:06:00Z","timestamp":1771038360152,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.psychres.2024.116070","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T18:15:37Z","timestamp":1719598537000},"page":"116070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER)"],"prefix":"10.1016","volume":"339","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0931-0999","authenticated-orcid":false,"given":"Hans Joachim","family":"de Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariken Beatrijs","family":"de Koning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke","family":"van Weringh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veroljub","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieuwe","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan Johannes","family":"Touw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Ignjatovic Ristic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psychres.2024.116070_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JCP.0000000000001657","article-title":"Feasibility and effect of increasing clozapine plasma levels in long-stay patients with treatment-resistant schizophrenia","volume":"43","author":"Bogers","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.psychres.2024.116070_bib0004","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40263-022-00932-2","article-title":"A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia","volume":"36","author":"Correll","year":"2022","journal-title":"CNS. Drugs"},{"issue":"5","key":"10.1016\/j.psychres.2024.116070_bib0005","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-resistant schizophrenia: definition, predictors, and therapy options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116070_bib0006","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2147\/NDT.S312095","article-title":"Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile","volume":"17","author":"de Filippis","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.psychres.2024.116070_bib0007","article-title":"An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine","volume":"35","author":"de Leon","year":"2022","journal-title":"Gen. Psychiatr."},{"issue":"2","key":"10.1016\/j.psychres.2024.116070_bib0008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.psc.2016.01.006","article-title":"Treatment-Resistant Schizophrenia","volume":"39","author":"Elkis","year":"2016","journal-title":"Psychiatr. Clin. North Am."},{"issue":"2","key":"10.1016\/j.psychres.2024.116070_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JCP.0000000000001653","article-title":"Clozapine: dose, sex, ethnicity, smoking habit, age, body weight, and plasma clozapine and N -desmethylclozapine (norclozapine) concentrations in clinical practice","volume":"43","author":"Flanagan","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.psychres.2024.116070_bib0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/2045125316677027","article-title":"Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit","volume":"7","author":"Gee","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2024.116070_bib0011","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.4088\/JCP.16m11164","article-title":"Dried blood spot analysis for therapeutic drug monitoring of clozapine","volume":"78","author":"Geers","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116070_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211065857","article-title":"Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples","volume":"12","author":"Geers","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psychres.2024.116070_bib0013","unstructured":"Group, t.N.C.C., 2013. Guideline for the use of clozapine."},{"issue":"1\u201302","key":"10.1016\/j.psychres.2024.116070_bib0014","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"PharmacoPsychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2024.116070_bib0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12888-021-03101-9","article-title":"Clinical validity of the 12-item WHODAS-2.0 in a naturalistic sample of outpatients with psychotic disorders","volume":"21","author":"Holmberg","year":"2021","journal-title":"BMC. Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2024.116070_bib0016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/08039488.2017.1400097","article-title":"The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder","volume":"72","author":"Ignjatovic Ristic","year":"2018","journal-title":"Nord. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2024.116070_bib0017","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.psychres.2024.116070_bib0018","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/NDT.S163839","article-title":"Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations","volume":"14","author":"Mayerova","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2024.116070_bib0019","series-title":"The Clozapine Handbook","author":"Meyer","year":"2019"},{"key":"10.1016\/j.psychres.2024.116070_bib0020","first-page":"14","article-title":"Review and management of clozapine side effects","volume":"61 Suppl 8","author":"Miller","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2024.116070_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211016189","article-title":"Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study","volume":"11","author":"Nomura","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.psychres.2024.116070_bib0022","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clinbiochem.2014.09.021","article-title":"Retrospective evaluation of therapeutic drug monitoring of clozapine and norclozapine in Belgium using a multidrug UHPLC-MS\/MS method","volume":"47","author":"Patteet","year":"2014","journal-title":"Clin. Biochem."},{"issue":"3","key":"10.1016\/j.psychres.2024.116070_bib0023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.rpsm.2020.05.003","article-title":"Clozapine in patients with schizoaffective disorder: a systematic review","volume":"14","author":"Rey Souto","year":"2021","journal-title":"Rev. Psiquiatr. Salud. Ment. (Engl. Ed)"},{"issue":"5","key":"10.1016\/j.psychres.2024.116070_bib0024","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/acps.13361","article-title":"Clozapine levels as a predictor for therapeutic response: a systematic review and meta-analysis","volume":"144","author":"Siskind","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.psychres.2024.116070_bib0025","first-page":"15","article-title":"Adverse drug reactions in relation to clozapine plasma levels: a systematic review","author":"Skokou","year":"2022","journal-title":"Pharmaceuticals. (Basel)"},{"issue":"Pt 4","key":"10.1016\/j.psychres.2024.116070_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1348\/014466502760387533","article-title":"The concurrent validity of the global assessment of functioning (GAF)","volume":"41","author":"Startup","year":"2002","journal-title":"Br. J. Clin. Psychol."},{"issue":"3","key":"10.1016\/j.psychres.2024.116070_bib0027","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00213-020-05746-y","article-title":"A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions","volume":"238","author":"Tan","year":"2021","journal-title":"Psychopharmacology. (Berl)"},{"issue":"6","key":"10.1016\/j.psychres.2024.116070_bib0028","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40262-023-01247-1","article-title":"Association between clozapine plasma concentrations and treatment response: a systematic review, meta-analysis and individual participant data meta-analysis","volume":"62","author":"Tralongo","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.psychres.2024.116070_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13264","article-title":"The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study","volume":"143","author":"Yada","year":"2021","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517812400355X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016517812400355X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T20:56:28Z","timestamp":1733172988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016517812400355X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"alternative-id":["S016517812400355X"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2024.116070","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine levels and outcomes in Serbian patients with treatment-resistant psychotic disorders previously treated without measuring clozapine levels (CLOSER)","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2024.116070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116070"}}